Systematically linking drug susceptibility to cancer genome aberrations

Related Experiment Video

Updated: Jun 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Martin L Sos1, Roman K Thomas

  • 1Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany.

Cell Cycle (Georgetown, Tex.)
|October 22, 2009
PubMed

Insights

Genetic aberrations in non-small cell lung cancer (NSCLC) predict responses to targeted therapies. This study identifies specific genetic lesions that make NSCLC cells susceptible to Hsp90 inhibitors and dasatinib.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Genetic aberrations drive cancer by altering cell signaling pathways.
  • Identifying drug-mutation relationships is crucial for targeted cancer therapy.
  • A systematic approach is needed to discover novel drug-mutation combinations.

Purpose of the Study:

  • To systematically screen non-small cell lung cancer (NSCLC) cell lines for drug susceptibility based on genetic lesions.
  • To identify novel drug-mutation combinations for NSCLC treatment.
  • To understand oncogenic pathway dependencies in NSCLC.

Main Methods:

  • Collected and characterized a panel of NSCLC cell lines with known genetic and phenotypic profiles.
  • Performed systematic screening to assess drug susceptibility correlated with specific genetic alterations.
  • Utilized geldanamycin-derived Hsp90 inhibitors and dasatinib (a SRC/ABL-inhibitor).

Main Results:

  • Identified specific genetic lesions that predict sensitivity to Hsp90 inhibitors.
  • Found that genetic lesions can predict response to the SRC/ABL-inhibitor dasatinib.
  • Demonstrated a correlation between genetic aberrations and drug activity in NSCLC.

Conclusions:

  • Genetic lesions in NSCLC can serve as biomarkers for predicting drug response.
  • This research advances the understanding of oncogenic pathway dependencies.
  • The findings can guide future drug development and define patient populations for targeted therapies.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...